Drug Response Testing and Repurposing Using Glioblastoma Organoid
Recruiting
Observational Study
Glioblastoma
Organoid
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 150 (estimated)
- Sponsor
- Chungnam National University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patie…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* primary or recurrent glioblastoma
* patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
* sufficient tumor sample is available for organoid culture
Exclusion Criteria:
* patients who are not underwent concurrent chemoradia…
Contacts